HPPK, which directly precedes DHPS in the folate biosynthetic pathway, is a promising but chronically under-exploited anti-microbial target. Here we report the identification of new S. enterica HPPK inhibitors, offering potential for new resistance circumventing S. enterica therapies as well as avenues for diversifying the current HPPK inhibitor space.

中文翻译：

---

虚拟筛选和体外验证确定了第一个报道的肠沙门氏菌 HPPK 抑制剂

HPPK 在叶酸生物合成途径中直接先于 DHPS，是一个有前景但长期未充分开发的抗微生物靶点。在这里，我们报告了新的肠沙门氏菌HPPK 抑制剂的鉴定，为规避肠沙门氏菌疗法的新耐药性提供了潜力，并为当前 HPPK 抑制剂领域的多样化提供了途径。